AF
PCRX icon

Allworth Financial’s Pacira BioSciences PCRX Stock Holding History

Allworth Financial’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Buy
426
+43
+11% +$1.02K ﹤0.01% 3666
2026
Q1 		$8.66K Buy
383
+45
+13% +$1K ﹤0.01% 3612
2025
Q4 		$8.75K Buy
338
+13
+4% +$309 ﹤0.01% 3357
2025
Q3 		$8.38K Sell
325
-30
-8% -$737 ﹤0.01% 3252
2025
Q2 		$8.48K Buy
355
+39
+12% +$983 ﹤0.01% 2977
2025
Q1 		$8.22K Hold
316
– – ﹤0.01% 2510
2024
Q4 		$7.09K Buy
316
+54
+21% +$948 ﹤0.01% 2595
2024
Q3 		$3.94K Buy
262
+178
+212% +$3.04K ﹤0.01% 2677
2024
Q2 		$1.63K Sell
84
-494
-85% -$14.1K ﹤0.01% 3010
2024
Q1 		$16.9K Sell
578
-4
-0.7% -$123 ﹤0.01% 1864
2023
Q4 		$19.6K Buy
582
+509
+697% +$14.9K ﹤0.01% 1660
2023
Q3 		$2.24K Buy
73
+65
+813% +$2.34K ﹤0.01% 2487
2023
Q2 		$321 Sell
8
-4
-33% -$165 ﹤0.01% 2999
2023
Q1 		$490 Buy
+12
New +$477 ﹤0.01% 2844
2017
Q1 		– Sell
-335
Closed -$11K – 803
2016
Q4 		$11K Hold
335
– – ﹤0.01% 391
2016
Q3 		$11K Buy
+335
New +$13.1K ﹤0.01% 402

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's PCRX Position: Q2 2026 in Review

Allworth Financial increased its Pacira BioSciences (PCRX) stake by 11% in Q2 2026, buying an estimated $1.02K and bringing the position to 426 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3666.

Allworth Financial first reported a position in PCRX in Q3 2016 and has held it in 16 quarters since. The position peaked at $19.6K in Q4 2023. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Allworth Financial held 426 shares of Pacira BioSciences worth $10.8K as of Q2 2026.
  • Allworth Financial bought 43 Pacira BioSciences shares in Q2 2026, an estimated $1.02K.
  • Pacira BioSciences made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3666 holding.
  • Allworth Financial first reported a position in Pacira BioSciences in Q3 2016 and has held it in 16 quarters since.
  • Allworth Financial's Pacira BioSciences position peaked at $19.6K in Q4 2023.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.